Cempra, U.S. Department of Health and Human Services infectious news
HHS’s Biomedical Advanced Research and Development Authority (BARDA) exercised its first option under a 2013 contract with Cempra to develop solithromycin ( CEM-101) to treat infections in pediatric populations and infections caused by bioterror threat pathogens. During the option segment, Cempra will receive $16 million to conduct a Phase Ib trial of solithromycin given intraveneously, as oral capules and as an oral suspension in up to 64 patients, ranging from newborns to those up to 17 years of age, with suspected or confirmed bacterial infections. Cempra will also begin startup activities for an international Phase II/III trial.
The initial base contract provided $17.7 million in funding for two years. The contract is worth up to $58 million total if it is extended for the full five years. ...